Spravato

Pharma giant Johnson & Johnson (NYSE:JNJ) announced Monday it had asked the Food and Drug Administration (FDA) to approve its nasal spray as a monotherapy for treatment-resistant depression (TRD) in adults. The New Jersey-based company's Spravato, contains esketamine as an active ingredient,...

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. But what exactly is Schedule III? What other substances are produced and studied in this...

Healthcare company Johnson & Johnson (J&J) (NYSE: JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:  Total reported sales of $21,351 million, a 6.8% increase compared to the same period in 2022. Of which U.S. sales totaled $11,996 million (...

Global pharmaceutical behemoth Johnson & Johnson (NYSE: JNJ) today announced results for their fiscal second quarter 2023. The company handily surpassed analyst forecasts by reporting adjusted earnings per share of $2.80 versus the consensus $2.62, and raised full year...

Delic Holdings Corp. (OTCQB: DELCF) owns and operates an umbrella of psychedelics-related businesses towards improving access to health benefits across the U.S., including one of the largest chain of psychedelic wellness clinics in the country, Ketamine Wellness Centers (KWC).  Besides the KWC...

Biotech stocks had a fairly decent outing in February, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB) adding roughly 2.7 percent for the month compared to the 3 percent gain for the S&P 500 Index. After the government shutdown-related slackness in January, FDA review picked up in...